A Case of Successful Treatment of Refractory Synovitis Acne Pustulosis Hyperostosis Osteitis (SAPHO) Syndrome with Adalimumab
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Synovitis acne pustulosis hyperostosis osteitis (SAPHO) syndrome is a rare disease that involves the skin, bones and joints. It is thought to be caused by infection with low-toxicity bacteria and to be the result of reactive infectious osteitis. However, this hypothesis has not yet been clearly established. New SAPHO syndrome treatment methods are needed because the disease does not respond to treatment in many cases. In this paper, a case is reported of SAPHO syndrome with pain in the acromioclavicular joint and with squamous and pustular macules on the palms and soles. First, the patient was treated with aceclofenac, prednisolon and sulfasalazine for two weeks. However, the symptoms were not relieved, so methotrexate and pamidronate were added to the treatment. Since no improvement was seen after four weeks of treatment, adalimumab was prescribed. The skin lesions were relieved two weeks later, and the bone pain and arthralgia, four weeks later. No recurrence or adverse effects were observed at the 22-week follow-up.
Abstract
Synovitis acne pustulosis hyperostosis osteitis (SAPHO) syndrome is a rare disease that involves the skin, bones and joints. It is thought to be caused by infection with low-toxicity bacteria and to be the result of reactive infectious osteitis. However, this hypothesis has not yet been clearly established. New SAPHO syndrome treatment methods are needed because the disease does not respond to treatment in many cases. In this paper, a case is reported of SAPHO syndrome with pain in the acromioclavicular joint and with squamous and pustular macules on the palms and soles. First, the patient was treated with aceclofenac, prednisolon and sulfasalazine for two weeks. However, the symptoms were not relieved, so methotrexate and pamidronate were added to the treatment. Since no improvement was seen after four weeks of treatment, adalimumab was prescribed. The skin lesions were relieved two weeks later, and the bone pain and arthralgia, four weeks later. No recurrence or adverse effects were observed at the 22-week follow-up.
참고문헌 (9)
- Chamot AM, "Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases", Rev Rhum Mal Osteoartic, 54, pp.187~196 (1987)
- Nguyen MT, "The SAPHO syndrome", Semin Arthritis Rheum, 42, pp.254~265 (2012)
- Müller-Richter UD, "SAPHO syndrome with ankylosis of the temporomandibular joint", Int J Oral Maxillofac Surg, 38, pp.1335~1341 (2009)
- Assmann G, "Efficacy of antibiotic therapy for SAPHO syndrome is lost after its discontinuation: an interventional study", Arthritis Res Ther, 11, pp.R140~ (2009)
- Assmann G, "The SAPHO syndrome--are microbes involved?", Best Pract Res Clin Rheumatol, 25, pp.423~434 (2011)
- Dougados M, "The European spondylarthropathy study group preliminary criteria for the classification of spondylarthropathy", Arthritis Rheum, 34, pp.1218~1227 (1991)
- Sallés M, "The SAPHO syndrome: a clinical and imaging study", Clin Rheumatol, 30, pp.245~249 (2011)
- Ben Abdelghani K, "Tumor necrosis factor-alpha blockers in SAPHO syndrome", J Rheumatol, 37, pp.1699~1704 (2010)
- Wendling D, "Anakinra treatment of SAPHO syndrome: short-term results of an open study", Ann Rheum Dis, 71, pp.1098~1100 (2012)